Antifungal activity of Taurolidine against Mucorales: An in vitro study on clinical isolates
Publish place: Current Medical Mycology، Vol: 8، Issue: 1
Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 93
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_CUMM-8-1_005
تاریخ نمایه سازی: 11 آذر 1402
Abstract:
Background and Purpose: Taurolidine is active against a wide variety of micro organisms, including bacteria and fungi. Mucormycosis is one of the life-threatening opportunistic fungal infections, especially in immunocompromised patients. Currently, the emergence of Mucormycosis during the COVID-۱۹ pandemic raises public health concerns regarding untoward morbidity and mortality among SARS-CoV-۲ patients. It is well-known that delayed and inappropriate antifungal therapy leads to increased morbidity and mortality. This study aimed to investigate the in-vitro antifungal activity of taurolidine to evaluate its effects against clinical isolates of Mucorales.Materials and Methods: This study included previously collected clinical Mucorales isolates. The minimum in vitro inhibitory concentration (MIC) of amphotericin B, caspofungin, voriconazole, posaconazole, and itraconazole was determined using the broth microdilution method.Results: All clinical isolates showed full sensitivity to amphotericin B. Posaconazole MIC range from ۸ μg/mL to ۰.۰۳۲ μg/mL. The MIC range of voriconazole and caspofungin were determined to be ۲-۸ µg/mL and ۰.۵-۱۶ µg/mL, respectively. Growth of the isolates was entirely inhibited in ۱۰۰۰ µg/mL concentration of taurolidine. In microscopic observations, morphological effects on hyphal growth were observed at ۵۰۰ µg/mL concentration.Conclusion: In conclusion, this is an updated experience of using taurolidine against Mucorales. However, our in-vitro findings need to be confirmed in well-designed clinical trials aimed at treating invasive Mucormycosis infections.
Keywords:
Authors
Hadis Jafarian
Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Ali Amanati
Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Parisa Badiee
Department of Pediatrics, Division of Pediatric Infectious Diseases, School of Medicine, Shiraz University
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :